Drug intelligence / Profile preview

WXSH0081

Development stage: Discontinued
Lead developer: Zhikang Hongren
Modality: Small Molecules
Administration: Oral

Overview

WXSH0081 is a small molecule drug candidate that was developed by Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd. It was investigated primarily for immune system diseases and digestive system disorders, with a particular focus on inflammatory bowel diseases. The drug reached Phase 1 clinical trials, which evaluated its safety, tolerability, pharmacokinetics (PK), and the effect of food on PK in healthy adult subjects. However, development has been discontinued and no further clinical advancement or approval has been reported[1][2][4].

Beyond the preview

Go deeper on WXSH0081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXSH0081.

Explore the full profile